Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cellectar Biosciences, Inc. (NASDAQ: CLRB).

Full DD Report for CLRB

You must become a subscriber to view this report.


Recent News from (NASDAQ: CLRB)

Cellectar Reports Recent Corporate Highlights and 2018 First Quarter Financial Results
MADISON, Wis., May 11, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today reported recent corporate highlights and financial results ...
Source: GlobeNewswire
Date: May, 11 2018 08:00
Your Daily Pharma Scoop: AcelRx Resubmits, MannKind Finds New Realms, VTVT Up On Mixed Data
Analysis focus: ACRX If you recall your AcelRx (NASDAQ: ACRX ), it got a CRL for DSUVIA lasy year citing safety concerns and drug administration issues. The exact things the FDA said, as reported by the company, were: “The two primary recommendations within the CRL are: first, while...
Source: SeekingAlpha
Date: May, 10 2018 10:00
Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma
MADISON, Wis., May 09, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces that the U.S. Food and Drug Administration (FDA) ...
Source: GlobeNewswire
Date: May, 09 2018 14:28
Your Daily Pharma Scoop: Achaogen Mixed Ad Com, Esperion Mixed Results, InVivo Up On Old Data
Analysis focus: AKAO So, the FDA Ad Com finally backed Achaogen’s (AKAO) plazomicin! While that is good that the committee voted 15-0 (1 abstain) in favor of the cUTI indication, it is not so good that they also voted 11-4 (1 abstain) that that the the data failed to provide subst...
Source: SeekingAlpha
Date: May, 04 2018 08:01
Blog Exposure - Cellectar Receives Rare Pediatric Disease Designation from FDA
Stock Monitor: Seattle Genetics Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 4, 2018 / If you want access to our free research report on Cellectar Biosciences, Inc. (NASDAQ: CLRB ) ("Cellectar") all you need to do is sign up now by clicking the following link www.active-inve...
Source: ACCESSWIRE IA
Date: May, 04 2018 07:30
Cellectar Bio's CLR 131 nabs rare pediatric disease tag in U.S., shares up 5% premarket
Thinly traded nano cap Cellectar Biosciences (NASDAQ: CLRB ) is up  5%  premarket on light volume in response to its announcement that the FDA has granted Rare Pediatric Disease Designation (RPDD) to PET imaging agent CLR 131 (18-(p-[131]-iodophenyl) octadecyl phosphocholine...
Source: SeekingAlpha
Date: May, 02 2018 09:03
Cellectar Receives Rare Pediatric Disease Designation for CLR 131 to Treat Neuroblastoma
MADISON, Wis., May 02, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today that the U.S. Food and Drug Administration (FDA) ...
Source: GlobeNewswire
Date: May, 02 2018 08:00
Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating Efficacy of Fractionated Injections of CLR 131 in Multiple Myeloma
MADISON, Wis., April 17, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today the presentation of a poster entitled “...
Source: GlobeNewswire
Date: April, 17 2018 08:00
Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating the Ability of its PDCs to Selectively Target a Broad Range of Tumor Cells
MADISON, Wis., April 16, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today the presentation of a late breaker poster entit...
Source: GlobeNewswire
Date: April, 16 2018 08:05
Preclinical Data Highlighting Uptake and Enhanced Anti-Tumor Effects of Cellectar's CLR 131 in Head and Neck Cancer Presented at AACR Annual Meeting
MADISON, Wis., April 16, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces the presentation of CLR 131 preclinical data in a pos...
Source: GlobeNewswire
Date: April, 16 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-203.142.7553.142.72310,795
2018-08-172.872.952.952.77187,944
2018-08-162.66042.8512.862.6659,078
2018-08-152.822.682.822.6568,800
2018-08-142.992.782.992.6585,704

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-2069,878139,98049.9200Short
2018-08-1725,57748,51852.7165Short
2018-08-1615,79236,63243.1098Short
2018-08-154,55723,50619.3865Cover
2018-08-1412,81548,43826.4565Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CLRB.


About Cellectar Biosciences, Inc. (NASDAQ: CLRB)

Logo for Cellectar Biosciences, Inc. (NASDAQ: CLRB)

Cellectar Biosciences is developing agents to detect, treat and monitor a broad spectrum of cancers. Utilizing a novel phospholipid ether PLE platform technology as a targeted delivery and retention vehicle, Cellectar s compounds are designed to be selectively taken up and retained in both cancer cells and cancer stem cells. With the ability to attach both imaging and therapeutic agents to its proprietary delivery platform, Cellectar has developed a portfolio of product candidates engineered to capitalize on the unique characteristics of cancer cells to find, treat and follow malignancies in a highly selective way. I CLR is a small molecule, broad spectrum, cancer targeted PET imaging agent. A Phase II trial evaluating I CLR in glioblastoma is expected to be completed in . Additionally multiple, investigator sponsored Phase I/II clinical trials are ongoing across solid tumor indications. I CLR is a small molecule, broad spectrum, cancer targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. Data from a Phase Ib dose escalation trial of I CLR in patients with advanced solid tumors is anticipated in the first quarter of . CLR is a preclinical, cancer targeted, non radioactive optical imaging agent for intraoperative tumor margin illumination and non invasive tumor imaging. For additional information please visit www.cellectar.com

 

Contact Information

 

 

Current Management

  • Simon Pedder / Acting CEO
  • J. Patrick Genn / VP, Business Development
  • Chad J. Kolean / VP, Fin., CFO, Treasurer
  • Kathryn McNeil / VP, Investor Relations and Corporate Affairs
  • Stephen A. Hill / Chairman
  • Paul Berns /
  • John Neis /
  • Jamey P. Weichert /

Current Share Structure

     


    Recent Filings from (NASDAQ: CLRB)

    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 11 2018
    Quarterly report with a continuing view of a company's financial position
    Filing Type: 10-QFiling Source: edgar
    Filing Date: May, 11 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 09 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 02 2018
    Official notification to shareholders of matters to be brought to a vote (Proxy)
    Filing Type: DEF 14AFiling Source: edgar
    Filing Date: April, 23 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 17 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 16 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 16 2018
    Preliminary proxy statement providing notification matters to be brought to a vote
    Filing Type: PRE 14AFiling Source: edgar
    Filing Date: April, 13 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 04 2018

     

     


    Daily Technical Chart for (NASDAQ: CLRB)

    Daily Technical Chart for (NASDAQ: CLRB)


    Stay tuned for daily updates and more on (NASDAQ: CLRB)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: CLRB)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CLRB is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CLRB and does not buy, sell, or trade any shares of CLRB. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/